Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson's disease.

ABSTRACT: Parkinson's disease is caused by the loss of dopamine neurons, causing motor symptoms. Initial cell therapies using fetal tissues showed promise but had complications and ethical concerns^1-5. Pluripotent stem (PS) cells emerged as a promising alternative for developing safe and effective treatments⁶. In this phase I/II trial at Kyoto University Hospital, seven patients (ages 50-69) received bilateral transplantation of dopaminergic progenitors derived from induced PS (iPS) cells. Primary outcomes focused on safety and adverse events, while secondary outcomes assessed motor symptom changes and dopamine production for 24 months. There were no serious adverse events, with 73 mild to moderate events. Patients' anti-parkinsonian medication doses were maintained unless ther

SUBMITTER: Sawamoto N 

PROVIDER: S-EPMC12095070 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature